In 2012, Glaucoma Research Foundation formed the Catalyst for a Cure (CFC) Biomarker Initiative with a goal to develop novel methods to detect, measure, and treat glaucoma with unprecedented precision. The research team was asked to identify and develop...
Read More »Catalyst for a Cure is a major collaborative research effort redefining how glaucoma research is conducted.
Read More »Richard A. Lewis, MD delivered the Glaucoma 360 New Horizons Forum keynote lecture in San Francisco on January 29, 2016.
Read More »Ike K. Ahmed, MD delivered the Keynote Lecture at the 7th annual Glaucoma 360 New Horizons Forum in San Francisco on February 9, 2018. His topic was “Interventional Glaucoma: The Why, The Who, and The How.”
Read More »Joel S. Schuman, MD, FACS, Chair of the Department of Ophthalmology at New York University's Langone Medical Center, delivered the New Horizons Forum keynote lecture in San Francisco on February 3, 2017.
Read More »"State of Glaucoma Therapy: 2012." George A. Cioffi, MD (Columbia University Medical Center) delivered the inaugural Glaucoma 360 - New Horizons Forum keynote lecture in San Francisco on February 3, 2012.
Read More »
Catalyst for a Cure is a team of four principal investigators and their laboratories working together to accelerate the pace of discovery toward a cure for glaucoma.
Read More »Glaucoma Research Foundation awards annual research grants for creative pilot projects that hold promise.
Read More »The Catalyst for a Cure Biomarker researchers are now evaluating their novel biomarkers in glaucoma patients. The newly identified markers of glaucoma can be detected with unique imaging devices developed by the team.
Read More »
Currently, all therapy for glaucoma is directed at lowering eye pressure, but the fundamental problem in glaucoma is the degeneration of the optic nerve fibers necessary for vision.
Read More »
